Valuation: Genmab A/S

Market Cap 223B 33.05B 29.89B 27.59B 24.97B 47.12B 3,107B 48.54B 331B 132B 1,661B 124B 121B 5,287B P/E 2026 *
41.2x
P/E 2027 * 32x
Enterprise Value 242B 35.79B 32.37B 29.88B 27.04B 51.03B 3,365B 52.56B 359B 143B 1,799B 134B 131B 5,726B EV / Sales 2026 *
8.09x
EV / Sales 2027 * 6.46x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.49%
1 week-1.45%
Current month-11.15%
1 month+40.73%
3 months+71.65%
6 months+106.41%
Current year+71.48%
1 week 3,472
Extreme 3472
3,728
1 month 2,404
Extreme 2404
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
01/12/25 Exercice

Director

189 0.0003%
01/12/25 Exercice

Director

189 0.0003%
01/12/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%-1.45%+76.94%+53.94% 33.05B
+1.10%-2.67%+62.79%+70.47% 68.45B
+0.74%+9.49%+16.18%+94.13% 61.31B
+0.09%+0.39%+20.52%+98.45% 55.73B
-0.96%+7.41%+10.20%+108.91% 47.51B
-1.25%+2.35%+22.74%+38.34% 44.68B
-2.41%-0.73%+167.89%+794.72% 38.14B
+1.21%-2.56%+20.27%+52.81% 35.85B
-2.22%+8.56%-39.26%+397.14% 25.9B
-4.38%-1.85%+35.56%-4.22% 25.57B
Average -0.96%+2.44%+39.38%+170.47% 44B
Weighted average by Cap. -0.56%+2.70%+40.12%+153.91%

Financials

2026 *2027 *
Net sales 29.93B 4.43B 4B 3.7B 3.34B 6.31B 416B 6.5B 44.35B 17.63B 222B 16.61B 16.26B 708B 36.34B 5.38B 4.86B 4.49B 4.06B 7.66B 505B 7.89B 53.86B 21.41B 270B 20.18B 19.75B 860B
Net income 5.37B 794M 718M 663M 600M 1.13B 74.62B 1.17B 7.95B 3.16B 39.89B 2.98B 2.92B 127B 7.34B 1.09B 982M 906M 820M 1.55B 102B 1.59B 10.87B 4.32B 54.55B 4.07B 3.99B 174B
Net Debt 18.53B 2.74B 2.48B 2.29B 2.07B 3.91B 258B 4.03B 27.46B 10.91B 138B 10.29B 10.07B 439B 11.18B 1.65B 1.5B 1.38B 1.25B 2.36B 156B 2.43B 16.57B 6.59B 83.14B 6.21B 6.08B 265B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,244
Date Price Change Volume
13/11/26 DKK 3,475.00 -1.56% 23,560
12/11/26 DKK 3,530.00 -0.87% 276,750
11/11/26 DKK 3,561.00 -0.56% 201,425
10/11/26 DKK 3,581.00 -2.19% 129,461
09/11/26 DKK 3,661.00 +3.80% 141,775
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,530.00DKK
Average target price
4,056.77DKK
Spread / Average Target
+14.92%
  1. Stock Market
  2. Stocks
  3. GMAB Stock